Fröhlich, A., Niebel, D., Fietz, S., Egger, E., Buchner, A., Sirokay, J., & Landsberg, J. (2020). Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients. http://lobid.org/resources/99370671253406441#!, 69(5):759-769. https://doi.org/10.1007/s00262-020-02487-x
Παραπομπή σε μορφή Chicago (17η εκδ.)Fröhlich, Anne, Dennis Niebel, Simon Fietz, Eva Egger, Andrea Buchner, Judith Sirokay, και Jennifer Landsberg. "Talimogene Laherparepvec Treatment to Overcome Loco-regional Acquired Resistance to Immune Checkpoint Blockade in Tumor Stage IIIB–IV M1c Melanoma Patients." Http://lobid.org/resources/99370671253406441#!, 69(5):759-769 2020. https://doi.org/10.1007/s00262-020-02487-x.
Παραπομπή σε μορφή MLA (9th εκδ.)Fröhlich, Anne, et al. "Talimogene Laherparepvec Treatment to Overcome Loco-regional Acquired Resistance to Immune Checkpoint Blockade in Tumor Stage IIIB–IV M1c Melanoma Patients." Http://lobid.org/resources/99370671253406441#!, 69(5):759-769, 2020, https://doi.org/10.1007/s00262-020-02487-x.